NovaBay Pharmaceuticals Files S-1/A Amendment
Ticker: NBY · Form: S-1/A · Filed: Jul 10, 2024 · CIK: 1389545
Sentiment: neutral
Topics: sec-filing, s-1/a, pharmaceuticals
Related Tickers: NBY
TL;DR
NovaBay Pharma (NBY) filed an S-1/A amendment on July 10. Details on securities.
AI Summary
NovaBay Pharmaceuticals, Inc. filed an S-1/A amendment on July 10, 2024, to its registration statement. The filing pertains to the company's securities and is registered under the Securities Act of 1933. NovaBay Pharmaceuticals, Inc. is incorporated in Delaware and its principal executive offices are located at 2000 Powell Street, Suite 1150, Emeryville, CA 94608.
Why It Matters
This filing is an update to NovaBay's registration statement, indicating ongoing efforts related to its securities offerings or corporate structure, which could impact investors and market perception.
Risk Assessment
Risk Level: medium — S-1/A filings often relate to capital raises or significant corporate changes, which carry inherent investment risks.
Key Numbers
- 333-280423 — SEC File Number (Identifies the specific registration filing with the SEC.)
- 2834 — SIC Code (Indicates the company operates in the Pharmaceutical Preparations industry.)
Key Players & Entities
- NovaBay Pharmaceuticals, Inc. (company) — Registrant
- 333-280423 (registration_number) — SEC File Number
- July 10, 2024 (date) — Filing Date
- 2000 Powell Street, Suite 1150 Emeryville, CA 94608 (address) — Principal Executive Offices
- Justin M. Hall (person) — Chief Executive Officer and General Counsel
- Squire Patton Boggs (US) LLP (company) — Legal Counsel
FAQ
What is the primary purpose of this S-1/A amendment?
The filing is an amendment to a registration statement under the Securities Act of 1933, indicating updates or changes to the company's securities offering or related disclosures.
When was this amendment filed with the SEC?
This amendment was filed on July 10, 2024.
Who is the Chief Executive Officer and General Counsel of NovaBay Pharmaceuticals, Inc.?
Justin M. Hall serves as the Chief Executive Officer and General Counsel.
What is the business address of NovaBay Pharmaceuticals, Inc.?
The principal executive offices are located at 2000 Powell Street, Suite 1150, Emeryville, CA 94608.
What is the company's Standard Industrial Classification (SIC) code?
The SIC code for NovaBay Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 4,596 words · 18 min read · ~15 pages · Grade level 15.8 · Accepted 2024-07-10 09:30:17
Key Financial Figures
- $0 — 9 shares of our common stock, par value $0.01, or common stock, Series F-1 common
- $2.30 — o purchase one share of common stock is $2.30. Each Series F-1 warrant will have an e
Filing Documents
- nby20240709_s1a.htm (S-1/A) — 593KB
- ex_696225.htm (EX-1.1) — 243KB
- ex_696226.htm (EX-4.16) — 124KB
- ex_696711.htm (EX-4.17) — 119KB
- ex_696227.htm (EX-4.18) — 115KB
- ex_696228.htm (EX-4.19) — 130KB
- ex_696229.htm (EX-5.1) — 15KB
- ex_696706.htm (EX-23.1) — 3KB
- ex_696712.htm (EX-FILING FEES) — 36KB
- a01.jpg (GRAPHIC) — 40KB
- a02.jpg (GRAPHIC) — 23KB
- a03.jpg (GRAPHIC) — 19KB
- logo01.jpg (GRAPHIC) — 9KB
- logo02.jpg (GRAPHIC) — 11KB
- logo.jpg (GRAPHIC) — 7KB
- 0001437749-24-022434.txt ( ) — 1526KB
Risk Factors
Risk Factors 13 Special Note Regarding Forward-Looking Statements 25
Use of Proceeds
Use of Proceeds 26 Dividend Policy 27
Dilution
Dilution 28 Principal Stockholders 30
Description of Capital Stock
Description of Capital Stock 31
Description of Securities We Are Offering
Description of Securities We Are Offering 35
Underwriting
Underwriting 37 Legal Matters 40 Experts 40 Where You Can Find More Information 40 Incorporation of Certain Documents by Reference 40 ABOUT THIS PROSPECTUS This registration statement filed with the Securities and Exchange Commission, or the SEC, includes exhibits and documents incorporated by reference that provide more detail on the matters discussed in this prospectus. You should read this prospectus, the related exhibits filed with the SEC and the documents incorporated by reference herein before making your investment decision. You should rely only on the information that we have included or incorporated by reference in this prospectus and any related free writing prospectus that we may authorize to be provided to you. We have not, and the underwriter has not, authorized anyone to provide you with information or to make any representation that is in addition to, or different from, that contained or incorporated by reference in this prospectus or contained in any permitted free writing prospectuses we have authorized for use in connection with this offering. If anyone provides you with different or inconsistent information, you should not rely on it as having been authorized by us in making a decision about whether to invest in the securities. We take no responsibility for, and cannot provide any assurance as to the reliability of, any other information that others may provide to you. The information contained in this prospectus, any related free writing prospectus and the documents incorporated by reference herein are accurate only as of their respective dates, regardless of the time of delivery of any such document or the time of any sale of the securities. Our business, assets, financial condition, results of operations and prospects may have changed since those dates. Therefore, you should not assume that the information contained in this prospectus or any related free writing prospectus is accurate on any date subsequent to the date set forth